Financial
FY2026 revenue $254.25bn (+14.0%); operating margin 1.0%; net income $1.71bn.
Cash $4.86bn; debt $8.89bn.
Cardinal Health
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Fair
Customer rating
No reviews yet
Financial health
Band: FairListed: CAH
FY2026 revenue $254.25bn (+14.0%); operating margin 1.0%; net income $1.71bn.
Cash $4.86bn; debt $8.89bn.
Source: official results release · Year ended 2026-06-30 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2026 | US$254.2bn | +14.0% | US$2.6bn | US$1.7bn | Cardinal Health |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Cardinal Health found in HSH's search of the last 24 months; lawsuit settlements found (kickbacks, opioid oversight) date from 2022. Aug 2025: Cardinal agreed to buy US urology group Solaris Health for $1.9bn.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Cardinal Health found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Jul 2026: Cardinal Health began a Class 2 FDA recall of 616 Presource surgical kits (US and Canada) containing third-party neurological sponges recalled for variable endotoxin levels.
Contract performance
Jun 2025: a large pharmaceutical distribution contract with Optum (UnitedHealth Group), reported as about 15% of revenue, expired, leaving Cardinal's reported sales roughly flat for the quarter.
Competitors
No competitors linked yet.